Analysis Group Releases Report on Biopharmaceutical Pipeline Innovation
January 21, 2013
Analysis Group has released a report that reviews and analyzes the current biopharmaceutical pipeline. The report, “Innovation in the Biopharmaceutical Pipeline: A Multidimensional View,” was coauthored by Senior Advisor Genia Long and Vice President Justin Works, who note that the current pipeline of new products and treatments in development reflects diverse clinical research programs across many different therapeutic areas. According to their research, about 8,000 biopharmaceutical projects are in clinical development, corresponding to more than 5,400 potential new treatments. The pipeline includes 1,800 projects for rare diseases and at least 400 for diseases for which no new therapies have been approved in at least a decade.
On January 17, 2013, Ms. Long participated in a Pharmaceutical Research and Manufacturers of America (PhRMA)-hosted webinar with Dr. John Lechleiter, Eli Lilly CEO and PhRMA chairman, and John Castellani, PhRMA president and CEO, to announce the new report and discuss how to ensure a favorable environment for innovation. According to Ms. Long, “Drug development remains an inherently risky undertaking, and there are no guarantees for success, but this report helps show the range of possible new therapies under development.” The report generated coverage from several media outlets, including USA Today and Forbes.
Read the report
View the webinar
Read about the report methodology on PhRMA’s Catalyst blog